Notably, mutations in genes encoding tyrosine kinase pathways effectors (especially KIT, FLT3 and RAS mutations) are found in up to 80% of CBF-AML patients [5–7]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.